Brain diffusion alterations in patients with COVID-19 pathology and neurological manifestations

被引:17
|
作者
Caroli, Anna [1 ]
Capelli, Serena [1 ]
Napolitano, Angela [2 ]
Cabrini, Giulia [3 ]
Arrigoni, Alberto [1 ]
Pezzetti, Giulio [2 ]
Previtali, Mattia [1 ]
Longhi, Luca Giovanni [4 ]
Zangari, Rosalia [5 ]
Lorini, Ferdinando Luca [6 ]
Sessa, Maria [7 ]
Remuzzi, Andrea [3 ]
Gerevini, Simonetta [2 ,8 ]
机构
[1] Ist Ric Farmacol Mario Negri IRCCS, Bioengn Dept, I-24020 Ranica, BG, Italy
[2] ASST Papa Giovanni XXIII, Dept Neuroradiol, I-24127 Bergamo, Italy
[3] Univ Bergamo, Dept Management Informat & Prod Engn, I-24044 Dalmine, BG, Italy
[4] ASST Papa Giovanni XXIII, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Bergamo, Italy
[5] ASST Papa Giovanni XXIII, FROM Res Fdn, I-24127 Bergamo, Italy
[6] ASST Papa Giovanni XXIII, Dept Emergency & Crit Care Area, Bergamo, Italy
[7] ASST Papa Giovanni XXIII, Dept Neurol, I-24127 Bergamo, Italy
[8] ASST Papa Giovanni XXIII, Dept Neuroradiol, Piazza OMS 1, I-24127 Bergamo, Italy
关键词
COVID-19; Diffusion weighted imaging; ADC; Neuroinflammation;
D O I
10.1016/j.nicl.2023.103338
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background and objective: COVID-19 neurological manifestations have been progressively recognized. Among available MRI techniques, diffusion weighted imaging (DWI) shows promise to study microstructure, inflammation, and edema. Previous DWI studies reported alterations in brain diffusivity in COVID-19 patients, as assessed by morphologic evaluation of brain DWI scans only. The aim of this study was to assess and quantify brain diffusion alterations in COVID-19 patients with neurological manifestations. Methods: 215 COVID-19 patients with neurological manifestations (olfactory and/or other neurological disorders) and 36 normal controls were compared and studied with DWI and T1-weighted MRI scans. MRI scans were processed by a semi-automatic processing procedure specifically developed for the purpose of this study, and the Apparent Diffusion Coefficient (ADC) was quantified in different brain tissues and individual white matter (WM) and gray matter (GM) regions. Differences in ADC values were assessed between COVID-19 patients and normal controls, as well as in the COVID-19 patient population grouped by hospitalization and neurological symptoms. Results: Among COVID-19 patients (median [IQR] = 52 [42 - 60] years of age, 58 % females), 91 were hospitalized and 26 needed intensive care. 84 patients had hyposmia/ageusia only, while 131 ones showed other neurological disorders. COVID-19 patients showed significantly increased ADC values in the WM and in several GM regions (p < 0.001). ADC values were significantly correlated with MRI time from disease onset (p < 0.05). Hospitalized patients showed significantly higher ADC alteration than non-hospitalized patients in all brain tissues; similarly, COVID-19 patients with neurological disorders showed significantly higher ADC values than those with olfactory loss only. ADC alteration was highest in patients with cognitive or memory disorder and in those with encephalitis or meningitis. ADC values were neither associated with the duration of hospitalization nor with the need for intensive care.Conclusion: Current findings suggest DWI potential as a non-invasive marker of neuroinflammation in COVID-19, and the transient nature of the same. Future longitudinal studies are needed to confirm our findings.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] From COVID-19 to long COVID; the forms of the neurological manifestations
    Ahuja, Sana
    Zaheer, Sufian
    JOURNAL OF MIND AND MEDICAL SCIENCES, 2023, 10 (02): : 209 - 216
  • [22] Neurological manifestations in COVID-19: an overview
    Mohseni Afshar, Zeinab
    Babazadeh, Arefeh
    Alizadeh Khatir, Ali
    Mohammadnia-Afrouzi, Mousa
    Javanian, Mostafa
    Vasigala, VeneelaKrishna R.
    Hosseinnia, Hajar
    Ebrahimpour, Soheil
    MINERVA RESPIRATORY MEDICINE, 2021, 60 (02): : 52 - 58
  • [23] Atypical Neurological Manifestations of COVID-19
    Gupta, Ishita
    Reddy, Mithun K.
    Hussain, Mir Mehdi
    Murthy, Pooja M.
    Robert, Chris A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [24] Brain Disease Network Analysis to Elucidate the Neurological Manifestations of COVID-19
    Prasad, Kartikay
    AlOmar, Suliman Yousef
    Alqahtani, Saeed Awad M.
    Malik, Md. Zubbair
    Kumar, Vijay
    MOLECULAR NEUROBIOLOGY, 2021, 58 (05) : 1875 - 1893
  • [25] Neurological manifestations as primary presentation of COVID-19 in hospitalized patients
    Chuang, David T.
    Aydemir, Seyhmus
    Magda, Paul
    Thomas, Crystal
    Zarnegar, Reza
    ACTA NEUROLOGICA SCANDINAVICA, 2021, 143 (05): : 569 - 574
  • [26] Brain Disease Network Analysis to Elucidate the Neurological Manifestations of COVID-19
    Kartikay Prasad
    Suliman Yousef AlOmar
    Saeed Awad M. Alqahtani
    Md. Zubbair Malik
    Vijay Kumar
    Molecular Neurobiology, 2021, 58 : 1875 - 1893
  • [27] Neurological Manifestations in COVID-19 Patients: A Meta-Analysis
    Vitalakumar, D.
    Sharma, Ankita
    Kumar, Anoop
    Flora, S. J. S.
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (15): : 2776 - 2797
  • [28] A Systematic Review of Neurological Manifestations of COVID-19
    Magar, Sumeru Thapa
    Lokhandwala, Hatim I.
    Batool, Saima
    Zahoor, Faiqa
    Zaidi, Syeda Kisa Fatima
    Sahtiya, Saveeta
    Khemani, Deepa
    Kumar, Sumeet
    Voloshyna, Diana
    Saleem, Faraz
    Ghaffari, Muhammad Abu Zar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [29] Neurological manifestations of COVID-19: a systematic review
    Nepal, Gaurav
    Rehrig, Jessica Holly
    Shrestha, Gentle Sunder
    Shing, Yow Ka
    Yadav, Jayant Kumar
    Ojha, Rajeev
    Pokhrel, Gaurab
    Tu, Zhi Lan
    Huang, Dong Ya
    CRITICAL CARE, 2020, 24 (01)
  • [30] Neurological manifestations of COVID-19, SARS and MERS
    Kato, Verstrepen
    Laure, Baisier
    Harald, De Cauwer
    ACTA NEUROLOGICA BELGICA, 2020, 120 (05) : 1051 - 1060